HRT may cause 39% higher risk of stroke
Women taking hormone replacement therapy have up to a 39% higher risk of suffering a stroke, according to a study by the Harvard Medical School in Boston, USA.
The study, published in the Archives of Internal Medicine, included 121,700 women aged between 30 and 55 who participated in the Nurses' Health Study. It found 360 cases of stroke amongst women who had never taken HRT versus 414 among current HRT patients.
According to the study, there is a 39% higher risk of stroke for women taking estrogen, and a 27% higher risk for those taking combination therapy of estrogen and progestin. The risk was equal for women initiating treatment at any age, before or after menopause, with the exception of those taking hormone therapy for less than five years at younger ages, although this may be related to the smaller number of cases representing that segment of the trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze